Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
CLK inhibitor rogocekib (development code: CTX-712)
Applicable field (uses covered by this announcement)
Relapsed or refractory acute myeloid leukemia (AML)
Relationship between the counterparty and the company
Chordia Therapeutics Inc.190A
CounterpartyMinistry of Health, Labour and Welfare
Award/certification name
Orphan drug designation
Awarding / certifying body
Ministry of Health, Labour and Welfare
Location (as indicated in this announcement)
Fujisawa, Kanagawa Prefecture (the company's head office)
Impact on Business Performance
This matter will have no impact on the Company's performance.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | CLK inhibitor rogocekib (development code: CTX-712) |
| Counterparty | Ministry of Health, Labour and Welfare |
| Applicable area | Relapsed or refractory acute myeloid leukemia (AML) |
| Award/certification name | Orphan drug designation |
| Awarding / certifying body | Ministry of Health, Labour and Welfare |
| Location | Fujisawa, Kanagawa Prefecture (the company's head office) |
| Impact on Business Performance | This matter will have no impact on the Company's performance. |
Items this document does not state (11)
Counterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateLaunch dateRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The orphan drug designation program supports research and development and promotes commercialization for diseases with small patient populations and high unmet medical needs. The designation makes the product eligible for support measures, including grants for testing and research expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.